References
- Goodisson LA, Bourne JT, Maharajan S. A case of bilateral peripheral ulcerative keratitis following treatment with rituximab. Rheumatology (Oxford). 2010;49(3):609–610. doi:10.1093/rheumatology/kep390.
- You C, Ma L, Lasave AF, Foster CS. Rituximab induction and maintenance treatment in patients with scleritis and granulomatosis with polyangiitis (Wegener’s). Ocul Immunol Inflamm. 2018;26(8):1166–1173. doi:10.1080/09273948.2017.1327602.
- Joshi L, Tanna A, McAdoo SP, et al. Long-term outcomes of rituximab therapy in ocular granulomatosis with polyangiitis: impact on localized and no localized disease. Ophthalmology. 2015;122(6):1262–1268. doi:10.1016/j.ophtha.2015.01.016.
- Suhler EB, Lim LL, Beardsley RM, et al. Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial. Ophthalmology. 2014;121(10):1885–1891. doi:10.1016/j.ophtha.2014.04.044.
- Babu K, Dharmanand BG. Worsening of posterior scleritis and orbital pseudotumor in a patient with granulomatosis polyangiitis with rituximab-A case report. Indian J Ophthalmol. 2020;68:1986–1988. doi:10.4103/ijo.IJO_1644_20.
- Dominguez-Casas LC, Sánchez-Bilbao L, Calvo-Río V, et al. Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients. Semin Arthritis Rheum. Aug 2020;50(4):608–615. doi:10.1016/j.semarthrit.2020.03.023.